Piera M, de Bolós C, Castro R, Real F X
Department d'Immunologia, Universitat Autònoma de Barcelona, Spain.
Int J Cancer. 1993 Aug 19;55(1):148-52. doi: 10.1002/ijc.2910550126.
Sialyl-Tn, defined by monoclonal antibody (MAb) B72.3, shows restricted normal-tissue distribution but is expressed in a wide variety of carcinomas. To analyze the immunogenicity of sialyl-Tn, mice were immunized with ovine submaxillary mucin (OSM) in combination with monophosphoryl lipid A (MPLA), liposomes, or adjuvants that activate macrophages (rIL-1, rIFN-gamma, rM-CSF, IL-1-derived peptides) or T cells (rIL-2). The level and specificity of the immune response were analyzed by ELISA. rIL-1 and rIFN-gamma induced a very high and specific antibody response, whereas the effect of rM-CSF was dose-dependent: at a low dose it induced a high-level specific antibody response and at the high dose level it induced a polyclonal non-specific response. These results indicate that cytokines are powerful adjuvants which modulate both the magnitude and specificity of the immune response. More studies are necessary to determine the optimal doses in animal models and in active specific immunotherapy of patients with cancer.
由单克隆抗体(MAb)B72.3所定义的唾液酸化Tn在正常组织中的分布有限,但在多种癌症中均有表达。为分析唾液酸化Tn的免疫原性,用羊下颌粘蛋白(OSM)与单磷酰脂质A(MPLA)、脂质体或激活巨噬细胞的佐剂(rIL-1、rIFN-γ、rM-CSF、IL-1衍生肽)或T细胞(rIL-2)联合免疫小鼠。通过酶联免疫吸附测定(ELISA)分析免疫反应的水平和特异性。rIL-1和rIFN-γ诱导出非常高且特异性的抗体反应,而rM-CSF的作用呈剂量依赖性:低剂量时诱导高水平的特异性抗体反应,高剂量时诱导多克隆非特异性反应。这些结果表明,细胞因子是强大的佐剂,可调节免疫反应的强度和特异性。需要更多研究来确定动物模型以及癌症患者主动特异性免疫治疗中的最佳剂量。